AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $44.900 million which beat the analyst consensus estimate of $6.351 million by 606.98 percent. This is a 780.39 percent increase over sales of $5.100 million the same period last year.